D-Index & Metrics Best Publications

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 123 Citations 66,579 844 World Ranking 1841 National Ranking 189

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Cancer
  • Surgery

His scientific interests lie mostly in Internal medicine, Breast cancer, Surgery, Oncology and Zoledronic acid. His Internal medicine study focuses mostly on Cancer, Chemotherapy, Metastasis, Bisphosphonate and Bone disease. His Breast cancer study incorporates themes from Randomized controlled trial and Clinical trial.

Robert E. Coleman combines subjects such as Hazard ratio, Placebo, Gastroenterology and Urology with his study of Surgery. His study explores the link between Oncology and topics such as Pathology that cross with problems in Positron emission tomography and Radiology. His biological study spans a wide range of topics, including Survival rate, Endocrinology, Adverse effect and Osteolysis.

His most cited work include:

  • Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer (1817 citations)
  • A Randomized Trial Of Exemestane After Two To Three Years Of Tamoxifen Therapy In Postmenopausal Women With Primary Breast Cancer. (1568 citations)
  • Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity (1438 citations)

What are the main themes of his work throughout his whole career to date?

Robert E. Coleman mainly focuses on Internal medicine, Oncology, Breast cancer, Surgery and Cancer. His study brings together the fields of Gastroenterology and Internal medicine. His study in the fields of Adjuvant under the domain of Oncology overlaps with other disciplines such as In patient.

His Breast cancer study combines topics from a wide range of disciplines, such as Clinical trial, Metastasis and Adjuvant therapy. His research in Surgery intersects with topics in Placebo and Urology. In his research, Bone pain is intimately related to Bisphosphonate, which falls under the overarching field of Zoledronic acid.

He most often published in these fields:

  • Internal medicine (61.11%)
  • Oncology (44.55%)
  • Breast cancer (37.39%)

What were the highlights of his more recent work (between 2014-2021)?

  • Internal medicine (61.11%)
  • Oncology (44.55%)
  • Breast cancer (37.39%)

In recent papers he was focusing on the following fields of study:

His primary scientific interests are in Internal medicine, Oncology, Breast cancer, Cancer and Surgery. Robert E. Coleman focuses mostly in the field of Internal medicine, narrowing it down to matters related to Placebo and, in some cases, Gastroenterology. The concepts of his Oncology study are interwoven with issues in Clinical trial, Metastatic breast cancer, Randomized controlled trial, Disease and Denosumab.

Robert E. Coleman has researched Breast cancer in several fields, including Cancer research, Metastasis and Hazard ratio. His work carried out in the field of Cancer brings together such families of science as Family medicine, Body mass index, MEDLINE and Intensive care medicine. His research on Surgery focuses in particular on Regimen.

Between 2014 and 2021, his most popular works were:

  • Adjuvant ovarian suppression in premenopausal breast cancer (418 citations)
  • Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials (378 citations)
  • Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials (293 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Cancer
  • Surgery

His main research concerns Internal medicine, Oncology, Breast cancer, Surgery and Prostate cancer. His Chemotherapy, Survival rate, Clinical trial, Hazard ratio and Clinical endpoint study are his primary interests in Internal medicine. The Chemotherapy study combines topics in areas such as Gastroenterology, Bisphosphonate and Anthracycline.

The various areas that he examines in his Oncology study include Cancer, Disease, Denosumab and Bone remodeling. His Breast cancer research includes elements of Randomized controlled trial, Intention-to-treat analysis and Metastasis. His studies examine the connections between Surgery and genetics, as well as such issues in Placebo, with regards to Adjuvant therapy and Hospital days.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

C. Parker;S. Nilsson;S. Nilsson;D. Heinrich;S. I. Helle.
The New England Journal of Medicine (2013)

3069 Citations

Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity

Robert E. Coleman.
Clinical Cancer Research (2006)

2361 Citations

A Randomized Trial Of Exemestane After Two To Three Years Of Tamoxifen Therapy In Postmenopausal Women With Primary Breast Cancer.

R. C Coombes;E. Hall;L. J. Gibson;R. Paridaens.
The New England Journal of Medicine (2004)

2325 Citations

Metastatic bone disease: clinical features, pathophysiology and treatment strategies.

R.E. Coleman.
Cancer Treatment Reviews (2001)

2151 Citations

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

Ian Smith;Marion Procter;Richard D Gelber;Sébastien Guillaume.
The Lancet (2007)

1852 Citations

The clinical course of bone metastases from breast cancer.

RE Coleman;RD Rubens.
British Journal of Cancer (1987)

1344 Citations

Adjuvant docetaxel for node-positive breast cancer.

Miguel Martin;Tadeusz Pienkowski;John R Mackey;Marek Pawlicki.
The New England Journal of Medicine (2005)

1305 Citations

Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.

Lee S. Rosen;David Gordon;Mary Kaminski;Anthony Howell.
Cancer Journal (2001)

1241 Citations

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.

Lee S Rosen;David Gordon;Mary Kaminski;Anthony Howell.
Cancer (2003)

1205 Citations

Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

RC Coombes;LS Kilburn;CF Snowdon;R Paridaens.
The Lancet (2007)

1053 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Robert E. Coleman

Fred Saad

Fred Saad

University of Montreal

Publications: 121

Jean-Jacques Body

Jean-Jacques Body

Université Libre de Bruxelles

Publications: 114

Allan Lipton

Allan Lipton

Penn State Milton S. Hershey Medical Center

Publications: 108

Gabriel N. Hortobagyi

Gabriel N. Hortobagyi

The University of Texas MD Anderson Cancer Center

Publications: 107

Michael Gnant

Michael Gnant

Medical University of Vienna

Publications: 85

Karim Fizazi

Karim Fizazi

University of Paris-Saclay

Publications: 85

Martine Piccart

Martine Piccart

Université Libre de Bruxelles

Publications: 82

Eric P. Winer

Eric P. Winer

Harvard University

Publications: 78

Nadia Harbeck

Nadia Harbeck

Ludwig-Maximilians-Universität München

Publications: 73

Richard D. Gelber

Richard D. Gelber

Harvard University

Publications: 72

Edith A. Perez

Edith A. Perez

Mayo Clinic

Publications: 70

Daniele Santini

Daniele Santini

Università Campus Bio-Medico

Publications: 69

Evangelos Terpos

Evangelos Terpos

National and Kapodistrian University of Athens

Publications: 68

Kathleen I. Pritchard

Kathleen I. Pritchard

University of Toronto

Publications: 67

Matthew R. Smith

Matthew R. Smith

Harvard University

Publications: 66

Johann S. de Bono

Johann S. de Bono

Institute of Cancer Research

Publications: 63

Trending Scientists

Shipeng Li

Shipeng Li

Chinese University of Hong Kong, Shenzhen

Mihai Surdeanu

Mihai Surdeanu

University of Arizona

Jorn H. Block

Jorn H. Block

University of Trier

Duan Weng

Duan Weng

Tsinghua University

Genxi Li

Genxi Li

Nanjing University

Marian Paluch

Marian Paluch

University of Silesia

Gulay Bayramoglu

Gulay Bayramoglu

Gazi University

Liang Huang

Liang Huang

Huazhong University of Science and Technology

William C Smith

William C Smith

Massey University

Judith Storch

Judith Storch

Rutgers, The State University of New Jersey

David K. Gardner

David K. Gardner

University of Melbourne

Bernard Cummings

Bernard Cummings

Princess Margaret Cancer Centre

Eric J. Feuer

Eric J. Feuer

National Institutes of Health

Donald O. Castell

Donald O. Castell

Medical University of South Carolina

Andrea Biviano

Andrea Biviano

National Institute for Astrophysics

Something went wrong. Please try again later.